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Abstract
The incidence of obesity is steadily rising, and it has been 
estimated that 40% of the US population will be obese by 
the year 2025 if the current trend continues. In recent years 
there has been renewed interest in the surgical treatment of 
morbid obesity in concomitance with the epidemic of obesity. 
Bariatric surgery proved effective in providing weight loss of 
large magnitude, correction of comorbidities and excellent 
short-term and long-term outcomes, decreasing overall 
mortality and providing a marked survival advantage. The 
Laparoscopic Sleeve Gastrectomy (LSG) has increased in 
popularity and is currently very "trendy" among laparoscopic 
surgeons involved in bariatric surgery. As LSG proved to be 
effective in achieving considerable weight loss in the short-
term, it has been proposed by some as a sole bariatric 
procedure. This editorial focuses on the particular advantages 
of LSG in the treatment of morbid obesity.
© 2008 WJG. All rights reserved.
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INTRODUCTION
The incidence of  obesity is steadily rising, and it has been 
estimated that 40% of  the US population will be obese by 
the year 2025 if  the current trend continues[1]. An alarming 
indicator of  the health crisis related to the epidemic of  
obesity is that 15% of  children and adolescents are obese 
(body mass index BMI > 95th percentile on the Centers 
for Disease Controls and Prevention standard charts), and 
over 20% are at risk (BMI > 85 percentile)[2]. In recent 
years there has been renewed interest in the surgical 
treatment of  morbid obesity in concomitance with the 
epidemic of  obesity, and application of  the laparoscopic 
techniques to the fi eld of  bariatric surgery as well. Bariatric 
surgery proved effective in providing weight loss of  large 
magnitude, correction of  comorbidities and excellent 
short-term and long-term outcomes[3-5], decreasing overall 
mortality and providing a marked survival advantage[6,7]. 
The number of  laparoscopic Roux-en-Y Gastric ByPass 
(LRYGBP) procedures have continued to increase in 
the last few years. This has contributed to the profound 
enthusiasm of  the surgical community for bariatric 
surgery. In this context, new bariatric procedures can 
be rapidly accepted by the surgical community, as has 
already happened in the case of  laparoscopic adjustable 
gastric banding (LAGB). The latter is a paradigm of  the 
“surgical enthusiasm” for a bariatric procedure. LAGB has 
rapidly reached wide diffusion, giving the label of  bariatric 
surgeon to any laparoscopic surgeon able to place a band 
around the stomach of  an obese patient. However, with 
time this procedure proved not to be the panacea that 
one would have thought it to be after its introduction. 
Due to a high rate of  long-term failure, the literature 
indicates fewer LAGB procedures and more Roux-en-Y 
gastric bypass (RYGBP) procedures are being performed, 
and surgeons are choosing laparoscopic RYGBP[8-10] 
The Laparoscopic Sleeve Gastrectomy (LSG) is being 
performed more frequently and is currently very “trendy” 
among laparoscopic surgeons involved in bariatric surgery. 
LSG is not a new operation as it is the restrictive part of  
a more complex malabsorbitive bariatric procedure; i.e., 
the biliopancreatic diversion with duodenal switch (BPD-
DS)[11,12]. Gagner and coworkers adapted the BDP-DS 
to the laparoscopic approach[13], and then introduced the 
concept of  the staged approach to very obese patients 
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with the LSG being the fi rst step[14]. As LSG proved to be 
effective in the short-term in achieving considerable weight 
loss, it has been proposed by some to be used solely as a 
bariatric procedure. 
SURGICAL TECHNIQUE 
LSG involves a longitudinal resection of  the stomach on 
the greater curvature from the antrum starting opposite of  
the nerve of  Latarjet up to the angle of  His. The fi rst step 
of  the procedure is the division of  the vascular supply of  
the greater curvature of  the stomach, which is achieved 
with the section of  the gastro-colic and gastro-splenic 
ligaments close to the stomach. The greater curvature must 
be completely freed up to the left crus of  the diaphragm 
to completely resect the gastric fundus that harbours the 
ghrelin secreting cells of  the stomach. The second step of  
the procedure is the longitudinal gastrectomy that “sleeves” 
the stomach to reduce it to a narrow tube. A naso-gastric 
tube is used to obtain a precise calibration and to avoid 
stenosis of  the gastric plasty. There is no consensus as to 
where to start the gastrectomy, and which calibre of  the 
naso-gastric tube to use. Gagner recommended starting 
the gastrectomy 10 cm proximal to the pylorus[14]. Baltazar 
recommended starting 4 cm from the pylorus in the case 
of  DS, and only 2 cm from it if  the LSG is intended as 
the sole bariatric procedure[15]. Different calibres of  naso-
gastric tubes have been reported by different authors 
from 32 Fr[15] to 60 Fr[14] The rational for starting closer 
to the pylorus and using a small calibre bougie to fashion 
the gastric tube is to increase the restrictive character of  
the procedure. The final volume of  the gastric tube has 
been reported to be as small as 60 mL[15] and as large as 
200 mL[13,14]. The staple line can then be reinforced with 
sutures or Seamguard to reduce the rate of  staple line leak 
or bleeding[16] (Figure 1).
PHYSIOLOGY OF LSG 
One of  the mechanisms involved in weight loss observed 
after the LSG is the dramatic reduction of  the capacity of  
the stomach. The concept of  restriction has been widely 
used in bariatric surgery in vertical banded gastroplasty 
(VBG) and LAGB. The distension of  the small gastric 
pouch in the LAGB procedure or VBG is supposed to 
account for the feeling of  early fullness, enhanced satiety 
and decreased hunger experienced by a patient after the 
ingestion of  small quantities of  food. The fact that the 
use of  small calibre nasal-gastric tubes, as small as 30 Fr 
for LSG as proposed by Baltazar, provides faster and 
increased weight loss is in favour of  the role of  mechanical 
restriction as an important determinant in terms of  weight 
loss that can be obtained with LSG[15].
The hormonal modifications induced by LSG differ 
from those found after a purely restrictive procedure as 
LASGB. Ghrelin, a peptide hormone mainly produced in 
the fundus of  the stomach, is supposed to be involved in 
the mechanisms regulating hunger and has been a focus 
of  interest in a growing number of  recently published 
papers[17]. Ghrelin is secreted by the endocrine cells of  
the stomach (X/A-like cells), which reside in the oxyntic 
glands of  the gastric fundus[18-20]. Gastric ghrelin producing 
cells are in contact with the basolateral membrane adjacent 
to the blood-stream and most of  them do not come 
in contact with gastric content[18-21]. The gastric fundus 
contains 10 to 20 times more ghrelin per 1 × g of  tissue 
than the duodenum[18-22] with diminishing concentrations 
being found in the jejunum and ileum[18,19,23]. Ghrelin has 
been also found in different additional tissues in very low 
concentrations such as the lungs, kidney, pancreatic islets, 
gonads, adrenal cortex, placenta and others[24]. Ghrelin 
regulates the secretion of  growth hormone release and is a 
potent orexigenic (appetite-stimulating) peptide. This last 
effect of  ghrelin is mediated by the activation of  ghrelin 
receptors in the hypothalamus/pituitary area[25]. 
There is some evidence that body weight is the major 
determinant in the long-term regulation of  the plasma 
concentration of  ghrelin[26,27]. Accordingly, it has been 
shown that plasma concentration of  ghrelin is increased in 
the case of  negative energy balance situations such as low-
calorie diets[26,28], chronic exercise[28,29], cancer anorexia[28], 
and anorexia nervosa[29], and are decreased in positive 
balance situations such as weight regain after overfeeding, 
or during the weight recovery phase of  anorexia 
nervosa[30] or in obese patients[31]. However as no putative 
mechanisms have been elucidated so far to explicate the 
changes in the plasma levels of  ghrelin in the long term, 
further studies are necessary to defi ne this issue. 
On the other hand, plasma concentration of  ghrelin 
is acutely regulated by the intake of  food with a meal to 
meal variation[31,32]. Plasma ghrelin concentration rises just 
before the onset of  meal and declines thereafter suggesting 
that ghrelin could play a role in the signal of  meal 
initiation[18,23,33,34], acting as the counterpart of  the several 
meal-related satiation factors such as cholecystokinin, 
peptide -YY, glucagons-like peptide 1. Although the 
mechanisms responsible for the postprandial suppression 
of  ghrelin are not known there is evidence that neither 
gastric nutrients nor gastric distension affect the plasma 
level of  ghrelin[35]. Different studies investigated the plasma 
levels of  ghrelin after different bariatric procedures, such 
as LASGB, LRYGBP and BPD[17]. Unfortunately, the 
results of  these studies are diffi cult to compare because the 
patients studied were in different states of  energy balance, 
the techniques of  sampling were different, and either the 
fasting or postprandial ghrelin levels were reported[17]. 
Nevertheless, there is overall evidence that LASGB is 
Figure 1  Laparoscopic sleeve gastre-
ctomy.
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associated with signifi cantly increased total plasma levels 
of  ghrelin as opposed to LRYGBP, which is followed by a 
decrease of  ghrelin[36-41]. 
As LASGB preserves the whole stomach, the gastric 
fundus, which is the major ghrelin producing tissue, is 
not excluded form contact with food. Ghrelin levels are 
increased with diet induced weight loss. Interestingly 
RYGBP has been shown to be associated with low levels 
of  circulating ghrelin that persist at 1 and 3 years follow-
up[42,43]. On the contrary, LASGB, VBG[44], and antirefl ux 
surgical procedures[37,45-48] are not associated with a decline 
of  the circulating levels of  ghrelin[42]. The most important 
difference between these procedures and LRYGBP 
is the contact of  food with the gastric fundus of  the 
stomach. The mechanism hypothesized to explain why 
ghrelin is down-regulated after LRYGBP is the override 
stimulation theory as described by Cummings. The empty 
stomach that is acutely associated with increased levels of  
circulating ghrelin would result in a continuous stimulatory 
signal that ultimately suppresses ghrelin production[23-26]. 
However, whether weight loss after LRYGBP is directly 
related to the changes in plasma levels of  ghrelin is still a 
matter of  debate[49].
Holdstock et al[50] found increased levels of  ghrelin
12 mo after GBP and argued that weight loss is not 
directly related to plasma concentration of  ghrelin. Faraj
et al[51] proposed that the plasma levels of  ghrelin are 
related to the state of  energy balance. During the period of  
weight loss after GBP, ghrelin is secreted by sources other 
than the stomach because of  the negative energy balance 
resulting in plasma levels higher than controls. Once 
patients have completed their weight loss phase and have 
reached a state of  energy balance, plasma levels of  ghrelin 
are comparable to those of  controls despite massive 
weight loss The disparate results reported in the literature 
on the mechanism involved in weight loss after LRYGBP 
imply that the relationship between the mechanical effects 
of  surgery and neuroendocrine response is complex and 
far from being clearly elucidated. 
Lager et al[52] reported significantly reduced levels of  
ghrelin in 10 obese patients undergoing LSG at 1 and 
6 mo after surgery. Interestingly, these patients were 
prospectively compared with 10 patients undergoing a 
LASGB procedure that resulted in signifi cantly increased 
levels of  ghrelin at 1 and 6 mo. This was paralleled by a 
superior weight loss in the group of  patients undergoing 
LSG, which might be related to the low levels of  circulating 
ghrelin with no compensatory hunger. In the case of  BPD, 
the circulating levels of  ghrelin are differently affected, 
depending on the type of  gastrectomy that is associated 
with the BPD. In the case of  BDP, according to Scopinaro, 
the gastric fundus is preserved and ghrelin levels are not 
reduced as reported by Adami et al[47]. On the contrary, 
when the BPD is associated with the pylorus preserving 
sleeve gastrectomy and duodenal switch (BPD-DS), the 
circulating levels of  ghrelin are markedly suppressed[53]. 
Ghrelin seems to play a key role in the complex energy 
balance loop and it is logical to hypothesize that its changes 
are involved in the neurophysiologic mechanisms responsible 
for the changes in appetite observed after bariatric surgery. At 
the moment, the short term results of  LSG are more similar 
to those observed after LRGBP than other purely restrictive 
procedures. Whether the observed change in circulating 
ghrelin level is a predictor of  the long-term success of  a given 
bariatric procedure, such as LSG, is not yet clear. 
PRO AND CONS OF LSG 
The seducing potential of  LSG relies in the fact that 
this operation is a straightforward procedure that can be 
generally completed laparoscopically, even in the case of  an 
extremely obese patient. It does not involve any digestive 
anastomosis, no mesenteric defects are created eliminating 
the risk of  internal hernia[54], no foreign material is used 
as in the case of  gastric banding, the whole digestive tract 
remains accessible to endoscopy, it is not associated with 
Dumping syndrome, the risk of  peptic ulcer is low and the 
absorption of  nutrients, vitamins, minerals and drugs is 
not altered. 
However, some points need to be underlined at 
least for those who are too enthusiastic about LSG. 
First, although LSG is generally an easy procedure, it 
may become a true nightmare in the very obese patient, 
especially in men with a huge left liver lobe, and the long 
staple line may leak postoperatively. Secondly, in face of  
the eventual regain of  lost weight or insufficient weight 
loss, the surgeon must be ready to do a second procedure 
that must be part of  his technical armamentarium. The 
last problem is represented by the choice of  the second 
procedure, which is traditionally the BPD-DS in the case 
of  patients with a BMI > 50. Other teams propose the 
LRYGBP but it is still not clear whether the latter can 
provide further weight loss in the case of  patients with 
an initial BMI > 50. The Scopinaro procedure or the 
VVLRYGBP are other alternatives, and the stomach might 
be re-sleeved in case of  gastric tube dilation.
RESULTS OF LSG
Only a few studies on sleeve gastrectomy for morbid 
obesity have been published so far. By performing a search 
in PubMed MEDLINE (National Library of  Medicine) for 
English-language articles published until March 2007 using 
the key words laparoscopic, sleeve gastrectomy, and considering 
only series reporting at least 30 patients, a total of  6 papers 
reporting a total of  328 cases was obtained[15,55-59]. Table 1 
summarizes relevant data collected from these articles.
Mean initial BMI ranged from 37.2 kg/m2[57,58] to 
65.4 kg/m2[56] with a case of  a patient with an extreme 
BMI at 91 kg/m2[56]. These data suggest that very high and 
even extreme BMI does not represent a contraindication 
to LSG. In fact, the two staged approach is becoming 
the rule in the case of  super-super obese patients (BMI 
> 60 kg/m2) in which more complex procedures such as 
RYGBP or biliopancreatic diversion are very difficult to 
perform. The rational of  the staged approach to super 
and super-super obese patients is to achieve a substantial 
weight loss with the consequent amelioration of  obesity-
related comorbidities with a simple procedure such as 
LSG, thus allowing the second procedure in patients with 
lower operative risks. Of  the 328 cases, data on gender 
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were available for 297 cases, for a total of  96 males (32%) 
and 201 females (68%) undergoing the procedure. In fact, 
beside high BMI, male gender is another important risk 
factor for postoperative morbidity and mortality and is 
associated with technical diffi culties at the time of  surgery. 
Men, in fact, often have an android body habitus whereby 
excess body fat is localized in the peritoneal cavity and 
the left lobe of  the liver is often enlarged rendering the 
access to the stomach and hiatal region diffi cult[55]. Thus, 
the relatively high percentage of  male patients undergoing 
SG in the literature reflects the choice of  the bariatric 
surgeon in favour of  SG, which is less challenging than 
other procedures requiring larger dissections and intestinal 
anastomoses.
In 3 o f  the 6 s tud ie s ana l yzed ( to ta l o f  130 
patients)[57-59], LSG was performed as the sole procedure; 
i.e. not followed by other types of  bariatric operations. 
However, one of  these pa t i en t s [57] underwent a 
laparoscopic gastric bypass one year after LSG because 
he failed to achieve a satisfactory weight loss. In the last 
3 studies, enrolling a total of  198 patients[15,55,56], LSG 
was intended as the fi rst step of  a combined approach to 
achieve an initial weight loss in “difficult” patients with 
the second step being a LRYGBP or DS. Among the 
198 patients undergoing the LSG as the fi rst step of  the 
combined approach strategy, 51 patients fi nally underwent 
the second procedure: 36 had a LRYGBP and 15 a DS. 
Interestingly, in the 3 studies in which LSG was performed 
as a first step procedure, only a part of  the initially 
programmed second procedures were finally performed. 
It can be speculated that at least in some of  the cases the 
weight loss achieved after LSG alone was satisfying[55,56,59].
Mean operative time was clearly reported in 4 of  the 
6 studies[55-57,59], ranging from 70 min[57] to 143 min[56]. As 
expected, the operative time is longer in patients with high 
BMI.
Unfortunately complete data about excess weight 
loss are reported in 3 of  the 6 studies[57-59]. This is a main 
concern as the primary outcome of  bariatric surgery 
is excess weight loss, and a given procedure cannot 
be evaluated correctly if  the functional results are not 
reported. Mean excess weight loss ranged from 52.8% 
(follow up 6 mo)[59] to 83.3% (follow up 12 mo). 
Three postoperative deaths were recorded for 328 
patients (death rate of  0.9%) and a total of  34 major and 
minor complications were reported (morbidity 10.3%). 
Fifteen of  these were considered minor complications: 
5 transient renal failures not requiring dialysis, 5 patients 
requiring ventilatory support for > 24 h, 1 pulmonary 
atelectasis, 1 case of  prolonged postoperative vomiting 
treated conservatively and spontaneously resolved, 3 
dehydrations. By excluding minor complications, a total 
of  19 major complications occurred (major complication 
rate 5.8%). Major complications managed conservatively 
included 4 cases of  staple-line leaks, 5 strictures of  the 
gastric plasty, 2 cases of  bleeding and 2 cases of  pulmonary 
embolus[55-57]. Six patients with major postoperative 
complications required re-operation. Re-operations were 
performed by laparoscopy in 4 cases of  intraperitoneal 
bleeding[12,49,51,52]. One case of  staple-line leak[59] and a case 
of  gastric ischemia required re-operation by laparotomy[58].
Bariatric surgery is associated with a mortality 
rate of  0.1-2.0 in large studies[60-64]. In a recent meta-
analysis by Buchwald et al[65], postoperative mortality was 
0.5% for RYGBP, 0.1% for gastric banding, and 1.1% 
for malabsorpitive procedures. In one of  the largest 
prospective studies[66], the SOS trial, postoperative 
complications occurred in 13% of  patients, including 
Table 1  Studies of Sleeve Laparoscopic Sleeve Gastrectomy including at least 30 patients
Study type Sample 
size
Sex Age(yr) Mean follow 
up (mo)
Death (%) Complications Mean operative 
time (min)
Initial BMI EWL (%) Reference
Retrospective 31 NA NA 3-27 3.2 n.1 bleeding 
(requiring laparoscopic
reoperation)
Gr 1: > 61
Gr 2: > 40  
Gr 3: 25-30  
Gr 4: NA
NA 15
Retrospective 60 8 M 30 (16-62) 12 1.6 1 leak 
1 delayed bleeding 
1 atelectasis
1postoperative 
vomiting
70 (45-100) 37.2 (30-56.1) NA 57 
Retrospective 126 59 M 49.5 (20-74) 12 0.8 5 strictures 
2 leaks 
2 pulmonary embolus 
5respiratory
insuffi ciencies 
4 renal failures
143 (90-120) 65.4 (45-91) 45 (for the 54 pts 
who underwent the 
phase ? operation 
LRYGBP)
56
Prospective 41 13 M 44.6 ± 9.7 22.2 0 1 leak 
1 transient renal 
failure bleeding
111 ± 31 57.3 ± 6.5 NA (but average BMI
after 1 yr was 
40.8 ± 8.5)
55 
Randomized 
prospective
(LSG vs gastric 
banding)
40 9 M 40 (22-65) 36 0 1 bleeding 
1 gastric ischemia
NA 39 (30-53) 66 58
Retrospective 30 7 M 40 (17-69) 6 0 3 dehydrations 1 leak 80 (65-130) 41.4 (33-59) 52.8 59
NA: Non Applicable; M: Men; EWL: Excess Weight Loss; min: Minutes; pts: Patients;  ref: Reference.
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bleeding in 0.5%, embolism or thrombosis in 0.8%, wound 
complications 1.8%, and pulmonary complications in 6.1%. 
In a recent review of  the literature, Baker et al[67] reported 
an average rate of  leak after LRYGBP of  2.77% (range 
0.3% to 8.3%). 
The evolution of  obesity related comorbidities after 
SG has not been clearly reported. However, SG should be 
effective in improving comorbidities, such as non alcoholic 
fatty liver disease/nonalcoholic steatohepatitis (NAFLD/
NASH)[68], as with any other procedure that induces weight 
loss because the improvement of  comorbidities is directly 
dependent on weight loss. Overall these results suggest 
that LSG is safe and effective in the short term to achieve 
a substantial weight loss. There is no evidence so far that 
weight loss obtained with LSG can be maintained in the 
long term. 
WEIGHT REGAIN AFTER LSG INDUCED
INITIAL WEIGHT LOSS 
In other words, can LSG be proposed as a sole bariatric 
procedure? When the LSG is done as the first step of  
a staged approach in very obese patients, the second 
procedure is generally done when the weight loss reaches 
a plateau, in the case of  weigh regain or simply when the 
patient can undergo more safely the second step regardless 
of  weight loss stabilization or regain. The possible 
mechanisms that account for the limited weight loss or 
weight regain include a technical problem, such as an 
incomplete resection of  the fundus of  the stomach where 
the ghrelin producing cells are located. This may occur 
in patients with hiatal hernia, which is often associated 
with excessive body weight[69]. Gastric dilatation has been 
evocated as being responsible for poor weight loss after 
LSG with or without DS[70]. An excessive large pouch 
may be the result of  an excessively large pouch created 
at the initial operation due to a too large calibration tube, 
or because of  inappropriate surgical technique such as 
missed posterior gastric folds. Excessive pressure against 
the pouch wall by large meals, repeated vomiting or distal 
obstruction may also account for pouch dilation[71]. Other 
factors may be claimed as responsible for poor weight 
loss or weight regain after LSG, such as the spontaneous 
dilation of  the gastric tube over time, the switch to a 
high caloric, soft, liquid diet, and, last but not least, LSG 
may have a limited potential for weight loss as do most 
restrictive procedures. 
The question whether the LSG may work as a sole 
bariatric procedure in the long term cannot be answered 
yet. For this reason LSG should be proposed as the fi rst 
step of  a staged approach in patients for whom a BPD-DS 
or LRYGBP seems too hazardous because of  very high 
BMI (super obesity-BMI > 50 or super-super obesity-BMI 
> 60), and/or associated diseases whether related or not to 
obesity. The decision to do a LSG may also be made during 
surgery in the case of  intraoperative fi ndings, such as liver 
cirrhosis, adhesions, too thick mesenteria contraindicating 
a more complex procedure. Then, the second step may be 
deferred until deemed necessary because of  insufficient 
weight loss or weight regain. On the other hand, the LSG 
should not be proposed to patients with a BMI < 50 until 
evidence is provided for its effectiveness in achieving 
weight loss in the long term compared to the results 
obtained with RYGBP, which remains the gold standard 
of  bariatric procedures at the moment. Exceptions might 
warrant a pure restrictive procedure, such as for patients 
with infl ammatory bowel disease for whom the intestinal 
bypass is not advised, and transplanted patients for whom 
the intestinal bypass may interfere with the absorption of  
immunosuppressive drugs. 
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